Lyra Therapeutics (LYRA) Competitors $0.12 0.00 (-2.36%) As of 11:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LYRA vs. CLGN, PYPD, NXL, IRIX, RVP, NEPH, QTI, PTHL, NXGL, and BSGMShould you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include CollPlant Biotechnologies (CLGN), PolyPid (PYPD), Nexalin Technology (NXL), IRIDEX (IRIX), Retractable Technologies (RVP), Nephros (NEPH), QT Imaging (QTI), Pheton Holdings Ltd Class A Ordinary Shares (PTHL), NEXGEL (NXGL), and BioSig Technologies (BSGM). These companies are all part of the "medical equipment" industry. Lyra Therapeutics vs. CollPlant Biotechnologies PolyPid Nexalin Technology IRIDEX Retractable Technologies Nephros QT Imaging Pheton Holdings Ltd Class A Ordinary Shares NEXGEL BioSig Technologies Lyra Therapeutics (NASDAQ:LYRA) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings. Do analysts prefer LYRA or CLGN? Lyra Therapeutics presently has a consensus target price of $1.25, indicating a potential upside of 977.59%. CollPlant Biotechnologies has a consensus target price of $12.50, indicating a potential upside of 477.37%. Given Lyra Therapeutics' higher probable upside, equities analysts plainly believe Lyra Therapeutics is more favorable than CollPlant Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00CollPlant Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has higher valuation & earnings, LYRA or CLGN? CollPlant Biotechnologies has lower revenue, but higher earnings than Lyra Therapeutics. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyra Therapeutics$1.53M4.98-$62.68M-$1.43-0.08CollPlant Biotechnologies$515K48.16-$7.02M-$1.46-1.48 Does the media refer more to LYRA or CLGN? In the previous week, Lyra Therapeutics and Lyra Therapeutics both had 2 articles in the media. Lyra Therapeutics' average media sentiment score of 0.93 beat CollPlant Biotechnologies' score of 0.43 indicating that Lyra Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Lyra Therapeutics Positive CollPlant Biotechnologies Neutral Does the MarketBeat Community prefer LYRA or CLGN? CollPlant Biotechnologies received 117 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. Likewise, 60.00% of users gave CollPlant Biotechnologies an outperform vote while only 58.54% of users gave Lyra Therapeutics an outperform vote. CompanyUnderperformOutperformLyra TherapeuticsOutperform Votes2458.54% Underperform Votes1741.46% CollPlant BiotechnologiesOutperform Votes14160.00% Underperform Votes9440.00% Do insiders and institutionals hold more shares of LYRA or CLGN? 95.6% of Lyra Therapeutics shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 3.3% of Lyra Therapeutics shares are owned by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, LYRA or CLGN? Lyra Therapeutics has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Is LYRA or CLGN more profitable? CollPlant Biotechnologies has a net margin of -2,680.00% compared to Lyra Therapeutics' net margin of -6,635.76%. CollPlant Biotechnologies' return on equity of -77.05% beat Lyra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lyra Therapeutics-6,635.76% -125.07% -59.74% CollPlant Biotechnologies -2,680.00%-77.05%-61.43% SummaryCollPlant Biotechnologies beats Lyra Therapeutics on 11 of the 18 factors compared between the two stocks. Get Lyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LYRA vs. The Competition Export to ExcelMetricLyra TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.64M$4.37B$5.53B$7.99BDividend YieldN/A39.94%5.11%4.23%P/E Ratio-0.0830.8122.6518.64Price / Sales4.9855.50401.98103.80Price / CashN/A51.0838.1834.62Price / Book0.076.096.754.30Net Income-$62.68M$68.71M$3.22B$248.44M7 Day PerformanceN/A-0.18%1.66%1.81%1 Month Performance-3.41%-2.33%4.17%4.40%1 Year Performance-97.79%23.51%16.17%5.97% Lyra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LYRALyra Therapeutics2.9296 of 5 stars$0.12-2.4%$1.25+977.6%-97.7%$7.64M$1.53M-0.0850Gap UpCLGNCollPlant Biotechnologies2.398 of 5 stars$2.24+1.0%$12.50+457.5%-63.9%$25.68M$515,000.00-1.4670Short Interest ↑Gap UpPYPDPolyPid2.1415 of 5 stars$2.52-3.1%$11.33+349.7%-40.3%$25.68MN/A-0.5180Upcoming EarningsShort Interest ↑News CoverageGap UpHigh Trading VolumeNXLNexalin Technology2.5439 of 5 stars$1.82-0.5%$5.00+174.7%+19.0%$24.26M$168,721.00-2.843IRIXIRIDEX2.1388 of 5 stars$1.30+6.6%$2.00+53.8%-58.2%$21.83M$48.67M-1.94120News CoverageHigh Trading VolumeRVPRetractable TechnologiesN/A$0.73-3.4%N/A-31.8%$21.71M$33.05M-1.34240Analyst ForecastGap UpNEPHNephros2.396 of 5 stars$1.95-3.0%$5.00+156.4%-11.9%$20.67M$14.16M-21.6730Upcoming EarningsShort Interest ↓News CoverageQTIQT ImagingN/A$0.73-3.9%N/A-5.1%$19.81M$4.00M0.00N/AUpcoming EarningsPTHLPheton Holdings Ltd Class A Ordinary SharesN/A$2.95-2.0%N/AN/A$19.42M$448,196.000.0011Positive NewsGap UpNXGLNEXGEL1.5317 of 5 stars$2.53flatN/A+23.1%$19.37M$8.69M-4.3610Short Interest ↓Positive NewsGap DownBSGMBioSig Technologies2.272 of 5 stars$1.04+13.0%$2.50+140.4%-38.0%$17.92M$40,000.000.0050Gap UpHigh Trading Volume Related Companies and Tools Related Companies CLGN Competitors PYPD Competitors NXL Competitors IRIX Competitors RVP Competitors NEPH Competitors QTI Competitors PTHL Competitors NXGL Competitors BSGM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LYRA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LYRA Stock Free LYRA Stock Alerts